Serum levels of lipid metabolites in age‐related macular degeneration
Open Access
- 17 July 2015
- journal article
- research article
- Published by Wiley in The FASEB Journal
- Vol. 29 (11) , 4579-4588
Abstract
Age‐related macular degeneration (AMD) is a neurodegenerative disease that causes adult‐onset blindness. There are 2 forms of this progressive disease: wet and dry. Currently there is no cure for AMD, but several treatment options have started to emerge making early detection critical for therapeutic success. Analysis of the eyes of Abca4 ‐/‐ Rdh8 ‐/‐ mice that display light‐induced retinal degeneration indicates that 11‐ cis ‐retinal and docosahexaenoic acid (DHA) levels were significantly decreased as compared with the eyes of control dark‐adapted C57BL/6J mice. In addition, exposure to intense light correlated with higher levels of prostaglandin G2 in the eyes of Abca4 ‐/‐ Rdh8 ‐/‐ mice. Intense light exposure also lowered DHA levels in the eyes of wild‐type C57BL/6J mice without discernible retinal degeneration. Analysis of human serum from patients with AMD recapitulated these dysregulated DHA levels and revealed dysregulation of arachidonic acid (AA) levels as well (∼32% increase in patients with AMD compared with average levels in healthy individuals). From these observations, we then built a statistical model that included levels of DHA and AA from human serum. This model had a 74% probability of correctly identifying patients with AMD from controls. Addition of a genetic analysis for one of the most prevalent amino acid substitutions in the age‐related maculopathy susceptibility 2 gene linked to AMD, Ala 69 →Ser, did not improve the statistical model. Thus, we have characterized a reliable method with the potential to detect AMD without a genetic component, paving the way for a larger‐scale clinical evaluation. Our studies on mouse models along with the analysis of human serum suggest that our small molecule‐based model may serve as an effective tool to estimate the risk of developing AMD.—Orban, T., Johnson, W. M., Dong, Z., Maeda, T., Maeda, A, Sakai, T., Tsuneoka, H., Mieyal, J. J., Palczewski, K. Serum levels of lipid metabolites in age‐related macular degeneration. FASEB J. 29, 4579‐4588 (2015). www.fasebj.orgKeywords
Funding Information
- National Institutes of Health
- National Eye Institute (EY009339, EY021126)
- Foundation Fighting Blindness
- Arnold and Mabel Beckman Foundation
This publication has 71 references indexed in Scilit:
- Translational biomarker discovery in clinical metabolomics: an introductory tutorialMetabolomics, 2012
- Primary amines protect against retinal degeneration in mouse models of retinopathiesNature Chemical Biology, 2011
- Three dimensional optical coherence tomography imaging: Advantages and advancesProgress in Retinal and Eye Research, 2010
- Neural mechanisms of ageing and cognitive declineNature, 2010
- Photoreceptor Layer Thinning over Drusen in Eyes with Age-Related Macular Degeneration Imaged In Vivo with Spectral-Domain Optical Coherence TomographyOphthalmology, 2009
- Molecular pathology of age-related macular degenerationProgress in Retinal and Eye Research, 2009
- Puzzles, promises and a cure for ageingNature, 2008
- A Stargardt disease‐3 mutation in the mouse Elovl4 gene causes retinal deficiency of C32–C36 acyl phosphatidylcholinesFEBS Letters, 2007
- A variant of mitochondrial protein LOC387715/ARMS2, not HTRA1, is strongly associated with age-related macular degenerationProceedings of the National Academy of Sciences, 2007
- Cigarette Smoking, CFH, APOE, ELOVL4, and Risk of Neovascular Age-Related Macular DegenerationArchives of Ophthalmology (1950), 2007